The company reported $46.8 million, compared with $47.6 million over the same period last year. Net revenues were also down $1.7 million in the third quarter of 2012, driven by the company’s biologics process.
International sales reached $15.9 million, $1 million more than the same period last year. As part of a January 2012 settlement, the company agreed to pay $18 million to Cross Medical for a license agreement dispute, with $1 million paid during the third quarter.
The company recently launched a new spinous process fixation system, BridgePoint, and a new synthetic bone growth biologic, Alphatec NEXoss.
More Articles on Orthopedic Devices:
Globus Medical 3Q Worldwide Sales Reach $94.8M, Up 12.5%
X-spine Announces FDA Approval for 2 Spine Systems
Zimmer Pulls Metal-on-Metal Hip Device From Australia
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
